Analysis of CD271-positive NSCLC as a potential therapeutic target

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K19437
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: KOSAI HITOMI 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 共同研究員 (70728203)
• Co-Investigator(Renkei-kenkyūsha): TANAKA Nobuyuki 地方独立法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 部長 (60280872)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 肺癌幹細胞

Outline of Final Research Achievements

CD271 has been shown to be a cancer stem cell marker of squamous cell carcinoma. To determine a potential role of CD271 in squamous cell carcinoma of the lung, CD271 was knock-downed by shRNA. CD271 mRNA knockdown inhibited both cell proliferation and migration. p42/44Erk inhibition as well as RhoA inhibition inhibited these malignant phenotypes. These malignant potential was delivered from the intra-cytoplasmic region of CD271. Together, CD271 is a potential target for squamous cell carcinoma type NSCLC therapy.

Free Research Field

呼吸器腫瘍学